Epithalon (Epitalon) – Research Compound Profile

Epithalon (Epitalon) – Research Compound Profile

Category: Peptide Bioregulator Research | Molecular Type: Synthetic Tetrapeptide (Ala-Glu-Asp-Gly) | Research Status: Investigational — Extensive Preclinical & Limited Human Trials

This page compiles published research data for qualified researchers. Epithalon is sold exclusively as a research compound and is not approved for human use.

Purchase for Research →

Molecular Overview

Epithalon (also referred to as Epitalon or Epithalone) is a synthetic tetrapeptide consisting of four amino acids — alanine, glutamic acid, aspartic acid, and glycine (AEDG). It was originally developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, based on the amino acid composition of Epithalamin, a polypeptide fraction derived from bovine pineal gland extract [1][2]. As a small tetrapeptide, Epithalon has a relatively low molecular weight and simple linear structure, which contributes to its stability and reproducibility in experimental settings.

The sequence contains two acidic residues (Glu, Asp) and no basic or aromatic residues, giving the molecule an overall negative charge at physiological pH and a high degree of aqueous solubility. The absence of tryptophan, methionine, and cysteine means the classical oxidative degradation routes relevant to larger peptides do not apply; the principal chemical liabilities for a short acidic tetrapeptide of this composition are backbone hydrolysis and, to a lesser extent, aspartate isomerization (Asp→iso-Asp) under prolonged storage at unfavorable pH. Epithalon represents one of the most extensively studied peptides in the field of bioregulator research, with over 25 years of published literature spanning in vitro cell culture systems, invertebrate models (Drosophila melanogaster), rodent models (CBA, SHR, and transgenic mice), non-human primate studies (rhesus monkeys), and a small number of human clinical investigations [1][3]. The primary research areas of interest include telomerase pathway activation, melatonin biosynthesis signaling, antioxidant defense, and tumor-related gene expression in these model systems.

Mechanism of Action

Epithalon’s most-studied mechanism of action is its reported interaction with the telomerase pathway, the ribonucleoprotein enzyme system responsible for maintaining telomere length at chromosome ends in dividing cells. Telomeres shorten with each cell division, and in cultured cell systems this shortening is associated with entry into replicative senescence. Khavinson et al. reported in 2003 that exposure of human fetal lung fibroblast cultures to Epithalon was associated with induction of telomerase catalytic subunit (hTERT) expression, activation of telomerase enzyme activity, and a measurable increase in telomere length relative to untreated cultures, with treated cultures continuing to divide for a substantially greater number of passages than untreated controls in that experiment [3][11]. A 2025 study by Ullah et al. reported comparable telomere-length increases in additional human cell lines, attributing the effect to both telomerase upregulation and alternative lengthening of telomeres (ALT) activity [12].

Beyond the telomerase pathway, Epithalon has been reported to act on the neuroendocrine system, specifically pineal gland signaling. The peptide has been shown in cell and animal studies to stimulate synthesis of arylalkylamine N-acetyltransferase (AANAT), the rate-limiting enzyme in melatonin biosynthesis, and to increase phospho-CREB transcription factor expression in pinealocytes [1][6]. In aged rhesus monkeys, Goncharova et al. (2001) reported that Epithalon administration was associated with changes in nocturnal melatonin secretion and diurnal cortisol rhythm that trended toward patterns observed in younger animals of the same colony [6][7]. A small 2012 human study reported that sublingual Epithalon over a defined study period was associated with an increase in urinary 6-sulfatoxymelatonin excretion and altered expression of circadian clock genes (Cry2 upregulated; Clock and Csnk1e downregulated) [10]. This melatonin-pathway signal has been of research interest because age-related decline in melatonin secretion is studied in connection with circadian regulation and oxidative-stress biology, though the human study was small and short in duration.

Epithalon has also been studied for antioxidant, antimutagenic, and tumor-related gene expression effects across multiple model organisms. In Drosophila melanogaster, Khavinson et al. (2003) reported that Epithalon reduced markers of lipid peroxidation (conjugated hydroperoxides and Schiff’s bases) at concentrations reported to be substantially lower than the melatonin concentrations required for comparable effects in the same assay [1][13]. In mouse models, Anisimov et al. (2003, 2001) reported reductions in chromosomal aberrations in bone marrow cells and reductions in spontaneous tumor incidence in Epithalon-exposed animals relative to untreated controls in those specific cohorts [14][15]. The peptide’s reported effects on tumor-related gene expression appear, per the cited authors, to be mediated in part by binding of the peptide to specific DNA sequences (ATTTC) in the telomerase gene promoter region, suggesting a possible epigenetic regulatory mechanism [1][16].

Interpretive limits: The majority of the mechanistic and outcome data summarized above originate from a single research group and its close collaborators, using small cohorts (in the human studies) or single-strain rodent colonies (in the animal studies). Telomerase activation in cultured fibroblasts and lifespan/tumor-incidence observations in specific mouse and Drosophila strains are findings within those closed experimental systems; they do not constitute evidence of an anti-aging or life-extension effect in humans, and none of the cited studies were designed or powered to demonstrate a longevity outcome in a general human population. Independent replication of the human clinical findings remains limited.

Published Research Parameters

The following table indexes the study models, durations, and reported observations of selected peer-reviewed publications. Dose, frequency, and administration-route details are deliberately omitted. This is a bibliographic index only — not a protocol and not a recommendation for any use.

Stability & Storage Characteristics

Published literature and peptide stability data provide the following characteristics relevant to laboratory handling of Epithalon:

• Lyophilized stability: As a small tetrapeptide in lyophilized form, Epithalon is reported to maintain stability over extended periods when stored at −20 °C (−4 °F). Shorter-term storage at 2–8 °C (35.6–46.4 °F) is considered acceptable for periods of several months [8].
• Reconstituted solution stability: Once reconstituted, peptide solutions are generally recommended to be stored at 2–8 °C (35.6–46.4 °F) and used within approximately 28 days, consistent with standard peptide handling guidance [8][9].
• Freeze-thaw sensitivity: Repeated freeze-thaw cycles can degrade reconstituted peptide solutions. Published peptide handling protocols advise against freezing reconstituted preparations [9].
• Light sensitivity: Reconstituted peptide solutions should be protected from light exposure during storage to minimize photodegradation [8].
• pH sensitivity: Because the sequence carries two acidic side chains and no basic residues, buffer pH during reconstitution and storage is a relevant variable for minimizing aspartate isomerization and maintaining chromatographic homogeneity over time.
• Tetrapeptide characteristics: Due to its small molecular size (four amino acids), Epithalon has limited secondary structure to disrupt, but standard aseptic handling and minimal temperature excursions remain best practices for maintaining integrity in research settings.

Analytical Characterization

Reverse-phase HPLC is the standard purity assay for synthetic Epithalon, resolving the intact tetrapeptide from truncated synthesis-related impurities and from the aspartate isomerization product that can form on extended storage. Electrospray or MALDI mass spectrometry confirms the expected monoisotopic mass; because the peptide is small and acidic, adduct formation (e.g., sodium or potassium adducts) is a common analytical artifact to control for during MS characterization. Amino acid analysis or quantitative peptide-content assay is the recommended basis for concentration determination rather than gross lyophilized mass, given the proportionally large contribution of counter-ion and residual moisture at this molecular weight. Chiral purity (confirming retention of the L-configuration at each stereocenter) and residual solvent/counter-ion quantitation are standard components of a quality assurance documentation for this class of short synthetic peptide.

Key Published Research Findings

The following findings are derived from published peer-reviewed studies. Each observation is attributed to the specific investigation in which it was reported, and quantitative outcome data have been described qualitatively below; see the cited sources for the original reported figures.

• Telomere-length findings in cultured human fibroblasts: In a 2003 Bulletin of Experimental Biology and Medicine study using human fetal lung fibroblast cultures, Khavinson et al. reported that Epithalon exposure was associated with hTERT induction, telomerase enzyme activation, and telomere elongation, with treated cultures continuing to divide for substantially more passages than untreated controls in that experiment [3][11]. In 2025, Ullah et al. reported comparable telomere-elongating effects in additional human cell lines, attributing the effect to both telomerase upregulation and ALT activity [12].

• Melatonin-pathway findings in aged primates: In a 2001 Bulletin of Experimental Biology and Medicine study using old rhesus monkeys, Goncharova et al. reported changes in nocturnal melatonin secretion and diurnal cortisol rhythm associated with Epithalon administration [6]. A 2004 follow-up study by the same group reported associated changes in glucose tolerance measures in aged primates [7].

• Melatonin and circadian gene expression in a small human study: In a 2012 Advances in Gerontology study of 75 women, Khavinson et al. reported that sublingual Epithalon administered over a defined short study period was associated with increased urinary 6-sulfatoxymelatonin excretion and altered circadian clock gene expression (Cry2 upregulated; Clock and Csnk1e downregulated) [10].

• Mortality outcomes in an elderly cohort (epithalamin): In a 2006 Bulletin of Experimental Biology and Medicine report, Korkushko et al. described a long-term placebo-controlled trial using epithalamin (the parent pineal extract from which Epithalon was derived) in elderly subjects with cardiovascular disease, reporting lower all-cause and cardiovascular mortality in the treatment group relative to placebo over the follow-up period [4]. As a single-center trial of the parent extract rather than the synthetic tetrapeptide itself, this finding is reported here for bibliographic completeness and has not been independently replicated in a comparable trial of Epithalon.

• Visual function measures in a clinical study population: In a 2003 Neuroendocrinology Letters clinical study of 162 human subjects with a retinal degenerative condition, Khavinson et al. reported improved visual acuity and expanded visual field measures in a majority of subjects, with no adverse effects reported in the study [17].

• Lifespan observations in an invertebrate model: In a 2003 Mechanisms of Ageing and Development study, Khavinson et al. reported an increase in imago lifespan in Drosophila melanogaster associated with Epithalon exposure at concentrations reported to be substantially lower than melatonin concentrations needed for a comparable antioxidant effect in the same assay [13].

• Lifespan and tumor-incidence observations in rodent models: In a 2001 Experimental Gerontology study, Anisimov et al. reported that Epithalon-exposed female CBA mice reached a greater maximum lifespan than controls in that specific cohort, with a concurrent reduction in spontaneous tumor incidence [15]. In a 2003 Biogerontology study in SHR mice, the same group reported a reduction in bone marrow chromosomal aberrations and a modest extension in the lifespan of the longest-lived survivors [14].

• Tumor-related gene expression in a transgenic mouse model: In a 2006 International Journal of Oncology study, Anisimov et al. reported that Epithalon exposure in HER-2/neu transgenic mice was associated with markedly lower HER-2/neu mRNA expression and reduced mammary tumor incidence relative to untreated controls [18].

• Neurogenic gene expression: In a 2020 Molecules study, Khavinson et al. reported that the AEDG peptide was associated with altered gene expression and protein synthesis during neurogenesis in the model system studied, with evidence of DNA binding at specific ATTTC sequences in the telomerase gene promoter region, suggesting a possible epigenetic regulatory mechanism [16].

Safety Profile in Published Literature

• Long-term clinical trial data: Clinical trials involving epithalamin (the parent extract) with multi-year treatment periods and follow-up in elderly subjects reported no severe adverse events attributable to the intervention [4][5].
• Retinal study safety: In the clinical study of 162 subjects with a retinal degenerative condition, no adverse effects were reported following Epithalon administration [17].
• Injection-site reactions (animal and clinical studies): Published studies noted occasional transient localized reactions (redness, warmth) at administration sites, consistent with general reactions reported for peptide administration in these studies [5].
• Telomerase and tumor risk (theoretical consideration): Because Epithalon has been reported to activate telomerase — an enzyme also active in many cancer cell lines — a theoretical concern exists regarding potential interaction with existing malignant processes. Published rodent data, however, have reported decreased spontaneous tumor incidence and reduced oncogene expression in Epithalon-exposed animals compared to untreated controls in those specific studies [14][15][18].
• Limited independent replication: The majority of published clinical and preclinical studies on Epithalon were conducted by Dr. Khavinson’s research group and close collaborators. Independent replication of these findings remains limited, though a 2025 study by Ullah et al. provided independent confirmation of the telomere-elongation findings in cultured human cells [5][12].
• Regulatory status: Epithalon has not been approved by any regulatory agency (including the FDA) for therapeutic use in humans.

Regulatory Status

• FDA approval: Epithalon is not approved by the U.S. Food and Drug Administration for any therapeutic indication.
• Clinical trial status: A limited number of clinical investigations have been conducted, primarily by Russian research groups. No active U.S.-registered clinical trials are currently listed on ClinicalTrials.gov for Epithalon.
• Research classification: Epithalon is classified and sold as a research compound intended for in vitro and preclinical investigation only.
• Independent assessment: The Alzheimer’s Drug Discovery Foundation has published a Cognitive Vitality report evaluating the available evidence for epithalamin and Epithalon, noting the limited scope of independent replication [5].

Research Use Only

All information on this page is provided for informational and citation purposes and summarizes findings from published scientific literature. Epithalon supplied by IronPeak Peptides LLC is intended for laboratory research purposes only. It is not a drug, food, or dietary supplement, is not intended for human or veterinary consumption, and is not intended to diagnose, treat, cure, mitigate, or prevent any disease, nor to extend lifespan or reverse aging in humans. Nothing on this page constitutes medical advice or a recommendation for use in humans. Handling should be performed only by qualified researchers in an appropriate laboratory setting.

References

1. Int J Mol Sci (2025) — Araj SK, Brzezik J, et al., “Overview of Epitalon—Highly Bioactive Pineal Tetrapeptide with Promising Properties.” Comprehensive review of 25+ years of Epitalon research including mechanisms, in vitro, in vivo, and clinical findings. View Source

2. Neuroendocrinology Letters (2001) — Khavinson VK, et al., “Synthetic tetrapeptide Epitalon restores disturbed neuroendocrine regulation in senescent monkeys.” Demonstrated melatonin normalization in aged primates. View Source

3. Bull Exp Biol Med (2003) — Khavinson VK, Bondarev IE, Butyugov AA, “Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells.” Study reporting telomere elongation in human fibroblasts. View Source

4. Bull Exp Biol Med (2006) — Korkushko OV, Khavinson VK, et al., “Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging.” Long-term RCT reporting lower mortality in the treatment group. View Source

5. Alzheimer’s Drug Discovery Foundation — Epithalamin/Epithalon Cognitive Vitality Report. Independent assessment of clinical evidence and safety profile. View Source

6. Bull Exp Biol Med (2001) — Goncharova ND, Khavinson VK, et al., “Effect of Epitalon on the age-related changes of pineal function in old monkeys.” Reported changes in nocturnal melatonin production and cortisol rhythms. View Source

7. Bull Exp Biol Med (2004) — Goncharova ND, et al., “Pineal peptides restore the age-related disturbances in hormonal functions of the pineal gland and the pancreas.” Reported changes in glucose tolerance and melatonin measures in old primates. View Source

8. JPT Peptide Technologies — “Peptide Stability: How Long Do Peptides Last?” General reference on lyophilized and reconstituted peptide storage practices. View Source

9. Tydes Laboratory — Bacteriostatic water and peptide reconstitution: general use-window guidance for reconstituted peptide solutions. View Source

10. Adv Gerontol (2012) — Khavinson VK, et al., “Effect of Epithalon on circadian gene expression and melatonin production.” Study of 75 women reporting increased 6-sulfatoxymelatonin excretion and modulation of Clock, Cry2, and Csnk1e gene expression. View Source

11. Bull Exp Biol Med (2004) — Khavinson VK, et al., “Peptide promotes overcoming of the division limit in human somatic cells.” Reported extended passage number in Epithalon-treated fetal fibroblasts versus controls. View Source

12. Biogerontology (2025) — Ullah M, et al., “Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity.” Independent confirmation of telomere-elongating effects via multiple pathways. View Source

13. Mech Ageing Dev (2003) — Khavinson VK, et al., “Effects of peptide Epitalon on lifespan of Drosophila melanogaster.” Reported increase in imago lifespan at low concentrations relative to melatonin. View Source

14. Biogerontology (2003) — Anisimov VN, et al., “Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female SHR mice.” Reported reduced bone marrow chromosomal aberrations and extended survivor lifespan. View Source

15. Exp Gerontol (2001) — Anisimov VN, Khavinson VK, et al., “Effect of Epithalon on the lifespan increase and spontaneous tumor incidence in female CBA mice.” Reported greater maximum lifespan and reduced tumor incidence versus controls. View Source

16. Molecules (2020) — Khavinson VK, et al., “AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis.” Demonstrated Epitalon’s influence on neurogenic gene transcription and potential epigenetic mechanisms via DNA binding. View Source

17. Neuroendocrinology Letters (2003) — Khavinson VK, et al., “Epithalon treatment of Retinitis pigmentosa.” Clinical study of 162 subjects reporting improved visual acuity, expanded visual fields, and no reported side effects. View Source

18. Int J Oncol (2006) — Anisimov VN, et al., “Effect of Epitalon on the development of mammary tumors in HER-2/neu transgenic mice.” Reported lower HER-2/neu mRNA expression and reduced tumor incidence in treated mice. View Source

⚠️ Disclaimer: This page is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Epithalon is sold exclusively as a research compound, has not been approved by the FDA for human consumption, and is not intended for human use, self-administration, or any anti-aging or life-extension application. All information is derived from published peer-reviewed literature. Research must comply with all applicable laws, regulations, and institutional guidelines.

Purchase Epithalon for Research →